Study compares immune responses from three major COVID-19 vaccine types

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...
TipRanks on MSN

MRNA, NVAX, BNTX: Here’s What Triggered a Sell-off in Major Vaccine Stocks Today

The memo, written by FDA chief medical and scientific officer Vinay Prasad, reviewed 96 pediatric deaths and concluded that ...

Moderna (MRNA): Reassessing Valuation After FDA Signals Tougher Vaccine Approval Standards

Moderna (MRNA) slipped about 6% after an FDA official said future vaccine approvals will face tougher scrutiny, a shift tied ...
BioSpace

Experts Decry Prasad Memo’s Lack of Transparency as Vaccine Stocks Dip

With no evidence to support the claim that 10 children died due to COVID-19 vaccines, experts unpack the impact of CBER chief ...
Science News

mRNA flu vaccines are making their way through clinical trials

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

Adjustable DNA 'shield' can control timing and rate at which mRNA produces proteins in vivo

RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...
Fierce Biotech

Pfizer's mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...